Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9*1/*3 and VKORC1‐1639G/A genotype

Lenvatinib inhibits CYP2C8. (S)‐Warfarin is metabolized to (S)‐7‐hydroxywarfarin by CYP2C9 and (S)‐4'‐hydroxywarfarin by CYP2C8. Here, we report drug interactions between warfarin and lenvatinib in a patient with CYP2C9*1/*3.

• Publication year

  2019

• Venue

  Journal of Clinical Pharmacy and Therapeutics

• Publication date

  2019-08-30

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/jcpt.13030PMID 31468576
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer

  2019cited by this paper
• Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation

  2019cited by this paper
• Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial

  2018cited by this paper
• Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

  2015cited by this paper
• Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

  2015cited by this paper
• Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

  2014cited by this paper
• Simultaneous Determination of Warfarin and 7-Hydroxywarfarin Enantiomers by High-Performance Liquid Chromatography With Ultraviolet Detection

  2011cited by this paper
• Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy

  2010cited by this paper
• Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients.

  2009cited by this paper
• Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.

  2009cited by this paper
• E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

  2008cited by this paper
• Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation

  2007cited by this paper
• Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.

  2006cited by this paper
• VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients

  2006cited by this paper
• Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

  2006cited by this paper
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

  2005cited by this paper
• A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

  2005cited by this paper
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

  2005cited by this paper
• Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

  2004cited by this paper
• Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

  2002cited by this paper
• Human P450 metabolism of warfarin.

  1997cited by this paper
• Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model

  1994cited by this paper
• Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin.

  1984cited by this paper
• A method for estimating the probability of adverse drug reactions

  1981cited by this paper

• Rapid Synthesis of Primary Amides Using Ammonia Borane.

  2025cites this paper
• Transamidation for the Synthesis of Primary Amides at Room Temperature.

  2020cites this paper
• Current treatment options for HCC: from pharmacokinetics to efficacy and adverse events in liver cirrhosis.

  2020cites this paper
• Lenvatinib/warfarin interaction

  2019cites this paper